Further investigation of the receptors and activation mechanisms for RELMβ might lead to a new class of agents that antagonize the pathological effects of RELMβ, and could serve as novel therapies for NAFLD/NASH. The gene discussed is RETNLB; the disease is metabolic dysfunction-associated steatohepatitis.